Stock Price Quote

TATVA CHINTAN PHARMA CHEM LTD.

NSE : TATVABSE : 543321ISIN CODE : INE0GK401011Industry : ChemicalsHouse : Private
BSE944.5517.8 (+1.92 %)
PREV CLOSE ( ) 926.75
OPEN PRICE ( ) 862.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 5810
TODAY'S LOW / HIGH ( )862.85 948.00
52 WK LOW / HIGH ( )610 1195.05
NSE944.8018.55 (+2 %)
PREV CLOSE( ) 926.25
OPEN PRICE ( ) 906.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 53126
TODAY'S LOW / HIGH( ) 899.00 948.00
52 WK LOW / HIGH ( )621 1222
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 12-06 1996
Management Info
Chintan Nitinkumar Shah - Chairman Chintan Nitinkumar Shah - Managing Director
Registered Office

Address Plot No 502/17,G I D C Estate,Ankleshwar,
Bharuch,
Gujarat-393002

Phone 07574848533 / 34

Email chintan@tatvachintan.com

Website www.tatvachintan.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

22May Clarification sought from Tatva Chint
The Exchange has sought clarification from Tatva Chintan Pharma Chem Ltd..
06May Tatva Chintan Pharma Chem bags export
Tatva Chintan Pharma Chem has received an export order worth of $35,55,0..
06May Tatva Chintan Pharma Chem zooms after
Tatva Chintan Pharma Chem is currently trading at Rs 770.00, up by 61.60..
26Mar Tatva Chintan Pharma Chem informs abou
Tatva Chintan Pharma Chem has informed that the ‘Trading Window’ for dea..
24Mar Tatva Chintan Pharma Chem informs abou
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit10.953.27000000000018
Gross Profit 15.54 4.61000000000018
Operating Profit 91.98294.05
Net Sales 1076.483664.15

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Tanfac Industries (BSE)
peergroup  3314.50 (8.34%)
M.Cap ( in Cr)3306.21
Solar Industries (BSE)
peergroup  16848.25 (1.21%)
M.Cap ( in Cr)152459.91
Jubilant Ingrevia (BSE)
peergroup  793.15 (16.58%)
M.Cap ( in Cr)12633.38
India Glycols (BSE)
peergroup  1891.40 (4.66%)
M.Cap ( in Cr)5856.06
Gujarat Fluorochemic (BSE)
peergroup  3737.30 (1.84%)
M.Cap ( in Cr)41054.24

Shareholding Pattern

PROMOTERS 72.02%
MUTUAL FUNDS/UTI 5.34%
NON-INSTITUTION 19.22%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Tatva Chintan Pharma Chem Ltd.

Tatva Chintan Pharma Chem Ltd. was incorporated in the year 1996. Its today's share price is 944.55. Its current market capitalisation stands at Rs 2209.5 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3797.12 Cr and Total Income of Rs.3861.85 Cr. The company's management includes Avani Rajesh Umatt, Subhash Ambubhai Patel, Manher Chimanlal Desai, Shekhar Rasiklal Somani, Ajaykumar Mansukhlal Patel, Chintan Nitinkumar Shah, Chintan Nitinkumar Shah, Ishwar Nayi.

It is listed on the BSE with a BSE Code of 543321 , NSE with an NSE Symbol of TATVA and ISIN of INE0GK401011. It's Registered office is at Plot No 502/17,G I D C Estate,AnkleshwarBharuch-393002, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are NDJ & Co, Pathak Anjaria & Co.

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.